Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|September 23, 2011

ECOG, ACRIN Join Forces

Author(s)Todd Neff

The American College of Radiology Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG) today unveiled their clinical research alliance: ECOG-ACRIN Cancer Research Group (ECOG-ACRIN).

The American College of Radiology Imaging Network (ACRIN) and the Eastern Cooperative Oncology Group (ECOG) today unveiled their clinical research alliance: ECOG-ACRIN Cancer Research Group (ECOG-ACRIN). 

“We are already actively engaged in the shared mission of reshaping the future of patient care through clinical research that leads to earlier cancer detection, more successful therapeutic intervention, greater rates of prevention, and more successful patient outcomes,” officials of the alliance said at the 2011 ACRIN Annual Meeting on Friday. They said their two respective National Cancer Institute cooperative groups have merged their oncology research activities into three core areas of emphasis:

• Early detection and diagnosis of cancer;

• Biomarker-driven Phase II and Phase III therapeutic studies for multiple cancer types and stages; and

• Genetic, molecular and imaging marker research to predict and monitor treatment response.

The organizations seek “bold integration of disciplines and technologies,” with an eye toward conducting “definitive, groundbreaking, biomarker-driven clinical research that promises to achieve patient-centered breakthroughs.”

Integration efforts are afoot and the group’s leadership is developing the business, administrative, and scientific framework for ECOG-ACRIN to sustain and streamline its combined research portfolio through public and private support, ECOG-ACRIN officials said.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.